HEADER HYDROLASE 14-NOV-11 4A7I TITLE FACTOR XA IN COMPLEX WITH A POTENT 2-AMINO-ETHANE SULFONAMIDE TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: FACTOR X LIGHT CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: DES-GLA FACTOR X LIGHT CHAIN, RESIDUES 84-179; COMPND 5 SYNONYM: FACTOR XA, COAGULATION FACTOR X, STUART FACTOR, STUART- COMPND 6 PROWER FACTOR; COMPND 7 EC: 3.4.21.6; COMPND 8 OTHER_DETAILS: MADE DES-GLA BY CHYMOTRYPSIN CLEAVAGE; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: ACTIVATED FACTOR XA HEAVY CHAIN XA; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: ACTIVATED FACTOR X HEAVY CHAIN, RESIDUES 235-488; COMPND 13 SYNONYM: FACTOR XA, COAGULATION FACTOR X, STUART FACTOR, STUART- COMPND 14 PROWER FACTOR; COMPND 15 EC: 3.4.21.6 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 TISSUE: BLOOD; SOURCE 6 MOL_ID: 2; SOURCE 7 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 8 ORGANISM_COMMON: HUMAN; SOURCE 9 ORGANISM_TAXID: 9606; SOURCE 10 TISSUE: BLOOD KEYWDS BLOOD COAGULATION FACTOR, CALCIUM- BINDING, EGF-LIKE DOMAIN, GAMMA- KEYWDS 2 CARBOXYGLUTAMIC ACID, GLYCOPROTEIN, HYDROLASE, HYDROXYLATION, SERINE KEYWDS 3 PROTEINASE, SERINE PROTEASE EXPDTA X-RAY DIFFRACTION AUTHOR M.NAZARE,H.MATTER,D.W.WILL,M.WAGNER,M.URMANN,J.CZECH,H.SCHREUDER, AUTHOR 2 A.BAUER,K.RITTER,V.WEHNER REVDAT 3 09-OCT-24 4A7I 1 REMARK REVDAT 2 01-MAY-24 4A7I 1 REMARK LINK REVDAT 1 01-FEB-12 4A7I 0 JRNL AUTH M.NAZARE,H.MATTER,D.W.WILL,M.WAGNER,M.URMANN,J.CZECH, JRNL AUTH 2 H.SCHREUDER,A.BAUER,K.RITTER,V.WEHNER JRNL TITL FRAGMENT DECONSTRUCTION OF SMALL, POTENT FACTOR XA JRNL TITL 2 INHIBITORS: EXPLORING THE SUPERADDITIVITY ENERGETICS OF JRNL TITL 3 FRAGMENT LINKING IN PROTEIN-LIGAND COMPLEXES. JRNL REF ANGEW.CHEM.INT.ED.ENGL. V. 51 905 2012 JRNL REFN ISSN 1433-7851 JRNL PMID 22190348 JRNL DOI 10.1002/ANIE.201107091 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 2002 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELYHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 200.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 12692 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.198 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.800 REMARK 3 FREE R VALUE TEST SET COUNT : 618 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2247 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 25 REMARK 3 SOLVENT ATOMS : 206 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 45.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 46.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.10200 REMARK 3 B22 (A**2) : 0.27600 REMARK 3 B33 (A**2) : -0.37800 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.323 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.757 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.316 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 3.021 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.571 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : MASK REMARK 3 KSOL : 0.37 REMARK 3 BSOL : 51.44 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : ION.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : A23.PAR REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : ION.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : A23.PAR REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: DISORDERED SIDE CHAINS WERE MODELED REMARK 3 STEREOCHEMICALLY. REMARK 4 REMARK 4 4A7I COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 14-NOV-11. REMARK 100 THE DEPOSITION ID IS D_1290050306. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 02-MAY-05 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.931 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 12692 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 19.660 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.04000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 21.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.48 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : 0.20000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 6.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX RIGID BODY REFINEMENT REMARK 200 STARTING MODEL: UNPUBLISHED FACTOR XA STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PROTEIN SOLUTION: 8 MG/ML PROTEIN, 5 REMARK 280 MM MES (PH 5.7), 5 MM CACL2, 100 MM BENZAMIDINE. RESERVOIR: 18- REMARK 280 20% PEG-600, 50 MM MES (PH 5.7). SOAKING: ADD 10 MM INHIBITOR. REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.12650 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 38.70800 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.02100 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 38.70800 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.12650 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.02100 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1830 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13220 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.7 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 TYR A -41 REMARK 465 LYS A -40 REMARK 465 ASP A -39 REMARK 465 GLY A -38 REMARK 465 ASP A -37 REMARK 465 GLN A -36 REMARK 465 CYS A -35 REMARK 465 GLU A -34 REMARK 465 THR A -33 REMARK 465 SER A -32 REMARK 465 PRO A -31 REMARK 465 CYS A -30 REMARK 465 GLN A -29 REMARK 465 ASN A -28 REMARK 465 GLN A -27 REMARK 465 GLY A -26 REMARK 465 LYS A -25 REMARK 465 CYS A -24 REMARK 465 LYS A -23 REMARK 465 ASP A -22 REMARK 465 GLY A -21 REMARK 465 LEU A -20 REMARK 465 GLY A -19 REMARK 465 GLU A -18 REMARK 465 TYR A -17 REMARK 465 THR A -16 REMARK 465 CYS A -15 REMARK 465 THR A -14 REMARK 465 CYS A -13 REMARK 465 LEU A -12 REMARK 465 GLU A -11 REMARK 465 GLY A -10 REMARK 465 PHE A -9 REMARK 465 GLU A -8 REMARK 465 GLY A -7 REMARK 465 LYS A -6 REMARK 465 ASN A -5 REMARK 465 CYS A -4 REMARK 465 GLU A -3 REMARK 465 LEU A -2 REMARK 465 PHE A -1 REMARK 465 THR A 0 REMARK 465 ARG A 51 REMARK 465 ARG B 245 REMARK 465 GLY B 246 REMARK 465 LEU B 247 REMARK 465 PRO B 248 REMARK 465 LYS B 249 REMARK 465 ALA B 250 REMARK 465 LYS B 251 REMARK 465 SER B 252 REMARK 465 HIS B 253 REMARK 465 ALA B 254 REMARK 465 PRO B 255 REMARK 465 GLU B 256 REMARK 465 VAL B 257 REMARK 465 ILE B 258 REMARK 465 THR B 259 REMARK 465 SER B 260 REMARK 465 SER B 261 REMARK 465 PRO B 262 REMARK 465 LEU B 263 REMARK 465 LYS B 264 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 1C -131.06 51.75 REMARK 500 ASN A 5 25.95 48.91 REMARK 500 GLN A 10 -109.88 -126.95 REMARK 500 ASN A 17 -175.14 72.06 REMARK 500 SER A 18 -175.17 57.33 REMARK 500 LYS A 34 -53.90 -133.94 REMARK 500 GLN B 75 -158.54 -152.75 REMARK 500 GLU B 76 83.63 -154.53 REMARK 500 ARG B 115 -169.48 -173.28 REMARK 500 SER B 214 -67.72 -105.97 REMARK 500 ALA B 221 17.13 55.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA B1245 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP B 70 OD1 REMARK 620 2 ASN B 72 O 72.0 REMARK 620 3 GLU B 80 OE2 84.6 152.3 REMARK 620 4 HOH B2037 O 73.4 98.8 59.3 REMARK 620 5 HOH B2038 O 72.2 67.5 119.8 145.5 REMARK 620 N 1 2 3 4 REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "BB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 6-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 7-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA B 1245 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE A7I B 1246 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5- CHLOROINDOL-2-YL) REMARK 900 SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-( PYRIDIN-4-YL)PYRIMIDIN-2-YL] REMARK 900 CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 2J34 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 REMARK 900 RELATED ID: 2Y5G RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 2W3K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4- DISUBSTITUTED REMARK 900 PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1 REMARK 900 RELATED ID: 2VWO RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX- 2212A,(2S) -(3'- REMARK 900 AMIDINO-3-BIPHENYLYL)-5-(4- PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR209685 REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA- REMARK 900 PENTASACCHARIDE COMPLEX REMARK 900 RELATED ID: 2VVV RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2Y5F RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 2XBX RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N-AMINO-15N- IMINO-13C- REMARK 900 METHYL)PHENOXY]-6-[3-(15N-AMINO-13C-METHYL )PHENOXY]-3,5-DIFLUORO-4- REMARK 900 METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR AND REMARK 900 MD SIMULATIONS. REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. REMARK 900 RELATED ID: 2VVU RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH REMARK 900 ECOTIN M84R REMARK 900 RELATED ID: 2G00 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-(( DIMETHYLAMINO) REMARK 900 METHYL)-4-BIPHENYLYL)-7-OXO-3-( TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO- REMARK 900 1H-PYRAZOLO[3,4 -C]PYRIDIN-1-YL)BENZAMIDE REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5- CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL]-6-METHOXYPHENYL]-4 -[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX- 2212A,(2S) -(3'- REMARK 900 AMIDINO-3-BIPHENYLYL)-5-(4- PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590 REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2VH0 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS:BIARYL REMARK 900 PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR200095 REMARK 900 RELATED ID: 2UWL RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. REMARK 900 RELATED ID: 2W3I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4- DISUBSTITUTED REMARK 900 PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2 REMARK 900 RELATED ID: 2JKH RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN REMARK 900 RELATED ID: 2UWP RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2XC4 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2Y81 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR132747 REMARK 900 RELATED ID: 2XC0 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165 REMARK 900 RELATED ID: 2Y7X RELATED DB: PDB REMARK 900 THE DISCOVERY OF POTENT AND LONG-ACTING ORAL FACTOR XA INHIBITORS REMARK 900 WITH TETRAHYDROISOQUINOLINE AND BENZAZEPINE P4 MOTIFS REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/FACTOR VIIA/ FACTORXA COMPLEX REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143 REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. REMARK 900 RELATED ID: 2UWO RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, REMARK 900 SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208707 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208815 REMARK 900 RELATED ID: 2XBY RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2XC5 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2Y7Z RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4- CHLOROPHENYL) REMARK 900 AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1- PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192 REMARK 900 RELATED ID: 2XBV RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471 REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR128515 REMARK 900 RELATED ID: 2VWL RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2VH6 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031 )COMPLEXED REMARK 900 WITH FACTOR XA REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. REMARK 900 RELATED ID: 2J4I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2Y5H RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR208944 REMARK 900 RELATED ID: 2VWN RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124 REMARK 900 RELATED ID: 2J94 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J95 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2CJI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1 REMARK 900 RELATED ID: 2J38 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2VVC RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2W26 RELATED DB: PDB REMARK 900 FATOR XA IN COMPLEX WITH BAY59-7939 REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125 REMARK 900 RELATED ID: 2VWM RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3-ADAMANTAN-1-YL -UREIDO)-3-(3- REMARK 900 CARBAMIMIDOYL-PHENYL)-N-PHENETHYL- PROPIONAMIDE REMARK 900 RELATED ID: 2Y82 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS REMARK 900 RELATED ID: 2Y80 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113 REMARK 900 RELATED ID: 2WYJ RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL -4,5,6,7- REMARK 900 TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6- REMARK 900 CHLORONAPHTH-2-YLSULPHONYL) PIPERAZINE REMARK 900 RELATED ID: 2FZZ RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO- 1,2- REMARK 900 BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1- PYRROLIDINYL)METHYL)-4- REMARK 900 BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1, 4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4- REMARK 900 C]PYRIDIN-7-ONE REMARK 900 RELATED ID: 2J2U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2XBW RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4- DICARBOXYLIC ACID REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2WYG RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 FXV673 REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476 DBREF 4A7I A -41 51 UNP P00742 FA10_HUMAN 84 179 DBREF 4A7I B 16 264 UNP P00742 FA10_HUMAN 235 488 SEQRES 1 A 96 TYR LYS ASP GLY ASP GLN CYS GLU THR SER PRO CYS GLN SEQRES 2 A 96 ASN GLN GLY LYS CYS LYS ASP GLY LEU GLY GLU TYR THR SEQRES 3 A 96 CYS THR CYS LEU GLU GLY PHE GLU GLY LYS ASN CYS GLU SEQRES 4 A 96 LEU PHE THR ARG LYS LEU CYS SER LEU ASP ASN GLY ASP SEQRES 5 A 96 CYS ASP GLN PHE CYS HIS GLU GLU GLN ASN SER VAL VAL SEQRES 6 A 96 CYS SER CYS ALA ARG GLY TYR THR LEU ALA ASP ASN GLY SEQRES 7 A 96 LYS ALA CYS ILE PRO THR GLY PRO TYR PRO CYS GLY LYS SEQRES 8 A 96 GLN THR LEU GLU ARG SEQRES 1 B 254 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 B 254 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 B 254 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 B 254 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 B 254 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 B 254 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 B 254 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 B 254 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 B 254 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 B 254 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 B 254 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 B 254 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 B 254 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 B 254 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 B 254 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 B 254 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 B 254 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 B 254 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 19 B 254 ARG GLY LEU PRO LYS ALA LYS SER HIS ALA PRO GLU VAL SEQRES 20 B 254 ILE THR SER SER PRO LEU LYS HET CA B1245 1 HET A7I B1246 24 HETNAM CA CALCIUM ION HETNAM A7I 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [2-(1--ISOPROPYL- HETNAM 2 A7I PIPERIDIN-4-YLSULFAMOYL)-ETHYL]-AMIDE FORMUL 3 CA CA 2+ FORMUL 4 A7I C15 H24 CL N3 O3 S2 FORMUL 5 HOH *206(H2 O) HELIX 1 1 LYS A 1B LEU A 3 5 5 HELIX 2 2 LEU A 3 CYS A 8 5 6 HELIX 3 3 ALA B 56 GLN B 61 5 6 HELIX 4 4 GLU B 124A LEU B 131A 1 9 HELIX 5 5 ASP B 164 SER B 172 1 9 HELIX 6 6 PHE B 234 THR B 244 1 11 SHEET 1 AA 2 PHE A 11 HIS A 13 0 SHEET 2 AA 2 VAL A 20 SER A 22 -1 O VAL A 20 N HIS A 13 SHEET 1 AB 2 TYR A 27 LEU A 29 0 SHEET 2 AB 2 CYS A 36 PRO A 38 -1 O ILE A 37 N THR A 28 SHEET 1 BA 7 GLN B 20 GLU B 21 0 SHEET 2 BA 7 LYS B 156 PRO B 161 -1 O MET B 157 N GLN B 20 SHEET 3 BA 7 THR B 135 GLY B 140 -1 O GLY B 136 N VAL B 160 SHEET 4 BA 7 PRO B 198 PHE B 203 -1 O PRO B 198 N SER B 139 SHEET 5 BA 7 THR B 206 TRP B 215 -1 O THR B 206 N PHE B 203 SHEET 6 BA 7 GLY B 226 LYS B 230 -1 O ILE B 227 N TRP B 215 SHEET 7 BA 7 MET B 180 ALA B 183 -1 O PHE B 181 N TYR B 228 SHEET 1 BB 7 GLN B 30 ILE B 34 0 SHEET 2 BB 7 GLY B 40 ILE B 46 -1 N PHE B 41 O LEU B 33 SHEET 3 BB 7 TYR B 51 THR B 54 -1 O LEU B 53 N THR B 45 SHEET 4 BB 7 ALA B 104 LEU B 108 -1 O ALA B 104 N THR B 54 SHEET 5 BB 7 ALA B 81 LYS B 90 -1 N GLU B 86 O ARG B 107 SHEET 6 BB 7 LYS B 65 VAL B 68 -1 O VAL B 66 N HIS B 83 SHEET 7 BB 7 GLN B 30 ILE B 34 -1 O LEU B 32 N ARG B 67 SSBOND 1 CYS A 1 CYS A 12 1555 1555 2.04 SSBOND 2 CYS A 8 CYS A 21 1555 1555 2.03 SSBOND 3 CYS A 23 CYS A 36 1555 1555 2.04 SSBOND 4 CYS A 44 CYS B 122 1555 1555 2.03 SSBOND 5 CYS B 22 CYS B 27 1555 1555 2.04 SSBOND 6 CYS B 42 CYS B 58 1555 1555 2.03 SSBOND 7 CYS B 168 CYS B 182 1555 1555 2.02 SSBOND 8 CYS B 191 CYS B 220 1555 1555 2.03 LINK OD1 ASP B 70 CA CA B1245 1555 1555 2.75 LINK O ASN B 72 CA CA B1245 1555 1555 2.71 LINK OE2 GLU B 80 CA CA B1245 1555 1555 3.06 LINK CA CA B1245 O HOH B2037 1555 1555 2.95 LINK CA CA B1245 O HOH B2038 1555 1555 2.85 SITE 1 AC1 8 ASP B 70 ASN B 72 GLN B 75 GLU B 76 SITE 2 AC1 8 GLU B 77 GLU B 80 HOH B2037 HOH B2038 SITE 1 AC2 15 GLU B 97 TYR B 99 PHE B 174 ALA B 190 SITE 2 AC2 15 GLN B 192 VAL B 213 TRP B 215 GLY B 216 SITE 3 AC2 15 GLY B 219 CYS B 220 GLY B 226 ILE B 227 SITE 4 AC2 15 TYR B 228 HOH B2031 HOH B2122 CRYST1 56.253 72.042 77.416 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017777 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013881 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012917 0.00000